Building access to the Regenstrief Institute is restricted through early 2021. More on our coronavirus precautions.
See our coronavirus precautions.

Regenstrief Institute research scientist Noll Campbell, PharmD, M.S., recently contributed to a study that made national headlines and provided more evidence that anticholinergic medications are linked to cognitive decline.

The results from the study, led by researchers at the University of California San Diego School of Medicine, were published in Neurology. The authors concluded that anticholinergics are associated with an increased risk of cognitive decline regardless of the presence of genetic or biomarker risk factors for Alzheimer’s disease.

Dr. Campbell consulted on the study, providing perspective on the data based on similar studies he has been involved with at Regenstrief and Indiana University School of Medicine.  He is listed as an author on the paper.

The past research conducted by Dr. Campbell and his colleagues also provides evidence establishing a link between the common type of medication and cognitive decline. He is now leading a clinical trial to determine if deprescribing anticholinergics improves cognition, which could in turn delay or prevent dementia.

In addition to his role as a research scientist at Regenstrief Institute, Dr. Campbell is an assistant professor of pharmacy practice at the Purdue University College of Pharmacy.

Related Influence

Dec 30, 2020 • Influence
Innovative FHIR-based decision support app named top 10 EHR story of 2020
Readers of Healthcare IT News chose a decision support application created by Regenstrief Institute, Indiana Health Information Exchange (IHIE), Indiana University Health and Indiana University School of Medicine as one of its top 10 EHR stories of 2020.   Healthcare IT News is a publication from the Healthcare Information and Management Systems Society (HIMSS) covering people, policy and technology driving innovations in healthcare. It published a list…
Continue Reading >
Dec 22, 2020 • Influence
Expanding telemedicine: Regenstrief CEO co-authors blog on AHRQ’s role in supporting telehealth research
The use of telemedicine has greatly increased during the COVID-19 pandemic. Regenstrief President and Chief Executive Officer Peter Embí, M.D., M.S., and fellow members of the Agency for Healthcare Research and Quality (AHRQ) National Advisory Committee authored a blog on the agency’s role in generating evidence to improve telemedicine.   The article identified the urgent need to fill significant evidence gaps regarding the…
Continue Reading >